home / stock / rytm / rytm news

RYTM News and Press, Rhythm Pharmaceuticals Inc. From 10/17/18

Stock Information
Company Name: Rhythm Pharmaceuticals Inc.
Stock Symbol: RYTM
Market: NASDAQ
Website: rhythmtx.com
Menu
RYTM RYTM Quote RYTM Short RYTM News RYTM Articles RYTM Message Board
Get RYTM Alerts

News, Short Squeeze, Breakout and More Instantly...
RYTM - Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals - New Horizons, Emerging Trends, and Upcoming Developments

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CURO Group Holdings Corp. (NYSE:CURO), BiondVax Pharmaceuticals Ltd. (NAS...
RYTM - Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer

BOSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the appointment of Murray W. Stewart, D....

RYTM - Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting

BOSTON, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that updated data from the company ...

RYTM - Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity

BOSTON, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of a new non-interventional ...
RYTM - Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference

BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Ex...

Previous 10 Next 10